Effect of different liver function Child-Pugh classification on clinical prognosis of hepatocellular carcinoma recipients after liver transplantation
-
摘要:
目的 探讨不同Child-Pugh分级对肝细胞癌(肝癌)肝移植受者术后肝癌复发和生存的影响。 方法 回顾性分析125例接受肝移植的肝癌受者临床资料,用Kaplan-Meier方法计算肝癌肝移植受者术后3年的无瘤生存率(DFS)和总生存率(OS)。采用Cox比例风险回归模型分析可能影响肝癌肝移植受者术后复发及生存的独立危险因素。 结果 中位随访时间为25.6个月,3年总的DFS和OS分别为68.4%和65.7%。Child-Pugh A、B级肝癌患者(113例)的3年DFS和OS分别是68.6%和66.2%,Child-Pugh C级肝癌患者(12例)的3年DFS和OS分别是66.7%和65.6%,两者差异均无统计学意义(均为P>0.05)。Cox回归分析结果表明,血管侵犯(P=0.001)和肿瘤数目>3个(P=0.025)是影响肝癌肝移植受者复发的独立危险因素。甲胎蛋白(AFP)> 400 μg/L(P=0.035)、血管侵犯(P=0.031)和肿瘤数目>3个(P=0.008)是影响肝癌患者生存的独立危险因素。 结论 Child-Pugh C级与A、B级肝癌患者肝移植术后预后无显著性差异,AFP、血管侵犯和肿瘤数目是影响肝癌患者肝移植术后预后的重要因素,肝移植可作为Child-Pugh C级肝癌患者的有效治疗手段。 Abstract:Objective To evaluate the effect of the different Child-Pugh classification on the recurrence and survival of hepatocellular carcinoma (HCC) recipients after liver transplantation. Methods Clinical data of 125 HCC recipients undergoing liver transplantation were retrospectively analyzed. The 3-year disease-free survival (DFS) and overall survival (OS) rates were calculated by Kaplan-Meier survival curve. The independent risk factors probably affecting the recurrence and survival of HCC recipients after liver transplantation were identified by using Cox's proportional hazards regression model. Results The median follow-up time was 25.6 months. The 3-year DFS and OS rates were 68.4% and 65.7% for all patients. The 3-year DFS and OS rates in 113 patients with Child-Pugh class A/B HCC were 68.6% and 66.2%, whereas 66.7% and 65.6% for 12 patients with Child-Pugh class C HCC with no statistical significance (all P>0.05). Cox's proportional hazards regression model demonstrated that vascular invasion (P=0.001)and the number of tumors>3 (P=0.025) were the independent risk factors for the postoperative recurrence of HCC in recipients undergoing liver transplantation. Alpha fetoprotein (AFP)>400μg/L (P=0.035), vascular invasion (P=0.031) and number of tumors>3 (P=0.008) were the independent risk factors affecting the survival of HCC patients. Conclusions The postoperative prognosis does not significantly differ between Child-Pugh class C and A/B HCC patients after liver transplantation. AFP, vascular invasion and number of tumors are the risk factors affecting the clinical prognosis of HCC patients after liver transplantation. Liver transplantation is an efficacious treatment for HCC patients with Child-Pugh class C. -
表 1 125例肝癌肝移植受者临床病理特征与预后多因素Cox回归分析结果
Table 1. Results of multivariate Cox regression analysis of clinicopathological features and prognosis in 125 hepatocellular carcinoma recipients after liver transplantation
影响因素 3年DFS 3年OS 相对危险度 95%置信区间 P值 相对危险度 95%置信区间 P值 Child-Pugh分级(A、B级/C级) – – 0.574 – – 0.114 血管侵犯(有/否) 3.106 1.565~6.165 0.001 2.300 1.080~4.899 0.031 肿瘤数目(≤3个/ > 3个) 2.292 1.107~4.744 0.025 3.148 1.352~7.331 0.008 AFP(≤400 μg/L或 > 400 μg/L) – – 0.147 2.168 1.056~4.451 0.035 肿瘤直径(≤4 cm/ > 4 cm) – – 0.126 – – 0.168 Milan标准(是/否) – – 0.895 – – 0.325 –为无数据 -
[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492. [2] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. [3] European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4):908-943. DOI: 10.1016/j.jhep.2011.12.001. [4] HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380. DOI: 10.1002/hep.29086. [5] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志, 2011, 16(10):929-946. DOI: 10.3969/j.issn.1009-0460.2011.10.017.Ministry of Health of the People' s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (2011 edition)[J]. Chin Clin Oncol, 2011, 16(10):929-946. DOI: 10.3969/j.issn.1009-0460.2011.10.017. [6] XIE DY, REN ZG, ZHOU J, et al. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr, 2017, 6(6):387-396. DOI: 10.21037/hbsn.2017.11.01. [7] SANGIOVANNI A, COLOMBO M. Treatment of hepatocellular carcinoma: beyond international guidelines[J]. Liver Int, 2016, 36 (Suppl 1):124-129. DOI: 10.1111/liv.13028. [8] VERSLYPE C, ROSMORDUC O, ROUGIER P, et al. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23(Suppl 7):vii41-vii48. http://d.old.wanfangdata.com.cn/Periodical/lcgdbzz201904013 [9] BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022. DOI: 10.1002/hep.24199. [10] MANZINI G, HENNE-BRUNS D, PORZSOLT F, et al. Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? a comparison of eight guidelines[J]. BMJ Open Gastroenterol, 2017, 4(1):e000129. DOI: 10.1136/bmjgast-2016-000129. [11] BENSON AB 3RD, ABRAMS TA, BEN-JOSEF E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers[J]. J Natl Compr Canc Netw, 2009, 7(4):350-391. doi: 10.6004/jnccn.2009.0027 [12] BENSON AB 3RD, D' ANGELICA MI, ABBOTT DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(5):563-573. doi: 10.6004/jnccn.2017.0059 [13] TOSO C, MAZZAFERRO V, BRUIX J, et al. Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma[J]. Am J Transplant, 2014, 14(10):2221-2227. DOI: 10.1111/ajt.12923. [14] OMATA M, LESMANA LA, TATEISHI R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(2):439-474. DOI: 10.1007/s12072-010-9165-7. [15] OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11(4):317-370. DOI: 10.1007/s12072-017-9799-9. [16] 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志, 2017, 33(8):1419-1431.DOI: 10.3969/j.issn.1001-5256.2017.08.003.National Health and Family Planning Commission of People' s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (2017 edition) [J]. J Clin Hepatol, 2017, 33(8):1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. [17] Korean Liver Cancer Study Group (KLCSG), National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma[J]. Korean J Radiol, 2015, 16(3):465-522. DOI: 10.3348/kjr.2015.16.3.465. [18] KOKUDO N, HASEGAWA K, AKAHANE M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines)[J]. Hepatol Res, 2015, 45(2). DOI: 10.1111/hepr.12464. [19] POON RT, CHEUNG TT, KWOK PC, et al. Hong Kong consensus recommendations on the management of hepatocellular carcinoma[J]. Liver Cancer, 2015, 4(1):51-69. DOI: 10.1159/000367728. [20] LU SN, WANG JH, SU CW, et al. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan[J]. J Formos Med Assoc, 2018, 117(5):381-403. DOI: 10.1016/j.jfma.2017.09.007.